Mucosal vs Systemic Influenza Vaccine While Breastfeeding: Milk Immunity

母乳喂养时粘膜疫苗与全身流感疫苗：乳汁免疫

• 批准号: 8581655
• 负责人: Pia S Pannaraj
• 金额: $ 13.35万
• 依托单位: CHILDREN'S HOSPITAL OF LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-14 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8581655
• 关键词: Adult; Advocate; Age-Months; Animal Model; Antibodies; Antibody Formation; Antigens; Attenuated; Attenuated Live Virus Vaccine; Blood; Breast Feeding; Cellular Immunity; Cessation of life; Child; Childhood; Clinical Research; Communicable Diseases; Data; Epidemiologic Studies; Evaluation; Foundations; Gene Expression; Gene Expression Profile; Genetic; Goals; Human; Human Milk; Immune; Immune response; Immunity; Immunization; Immunoglobulin A; Inactivated Vaccines; Infant; Infection; Influenza; Influenza vaccination; Investigation; Knowledge; Life; Lymphoid Tissue; Mammary gland; Maternal antibody; Milk; Molecular Profiling; Morbidity - disease rate; Mothers; Mucosal Immunity; Nasopharynx; Nose; Pregnancy; Pregnant Women; Public Health; Research; Risk; Route; Seasons; Severity of illness; Testing; Vaccinated; Vaccination; Vaccines; Vulnerable Populations; Woman; age group; anti-influenza; experience; improved; influenza virus vaccine; mortality; mucosa-associated lymphoid tissue; mucosal vaccination; novel; peripheral blood; prevent; public health relevance; research study; response; vaccination strategy; vaccine delivery; vaccine efficacy

DESCRIPTION (provided by applicant): Infants are at increased risk for serious complications from influenza, with morbidity rates exceeding even adults >65 years. Unfortunately, influenza vaccines are ineffective in infants <6 months of age. This biologically vulnerable group relies on maternal antibody for protection. Public health officials advocate maternal immunization; however, there is no data on which type of maternal influenza vaccine best protects infants. We seek to compare maternal response to the systemic inactivated influenza vaccine (TIV) and the intranasal live-attenuated influenza vaccine (LAIV). Because the lactating mammary gland is part of mucosa-associated lymphoid tissue, we hypothesize that mucosally-administered LAIV will elicit higher levels of anti-influenza immunity in breast milk than vaccination with the injeced TIV. We will evaluate levels of influenza-specific antibodies and cellular immunity in blood and breast milk. We also will compare levels of influenza-specific responses in TIV and LAIV recipients. Finally, we will perform gene expression experiments to identify gene expression patterns induced after vaccination to further understand differences in innate and adaptive immune responses. Our data will provide a comprehensive analysis of the mechanisms underlying immune protection during breastfeeding. Moreover, the experience and knowledge gained from this proposal will lay the foundation for an R01 application for support for further investigations of how to optimize this maternal vaccination strategy for the protection of infants against influenza and other infectious diseases.

描述（由申请人提供）：婴儿患流感严重并发症的风险增加，发病率甚至超过 65 岁以上的成年人。不幸的是，流感疫苗对 6 个月以下的婴儿无效。这个生物学上的弱势群体依赖母体抗体来保护。公共卫生官员提倡孕产妇免疫；然而，没有关于哪种类型的孕产妇流感疫苗最能保护婴儿的数据。我们试图比较母亲对全身灭活流感疫苗（TIV）和鼻内减毒流感疫苗（LAIV）的反应。由于哺乳期乳腺是粘膜相关淋巴组织的一部分，我们假设粘膜注射 LAIV 会在母乳中引发比注射 TIV 疫苗更高水平的抗流感免疫力。我们将评估血液和母乳中流感特异性抗体和细胞免疫的水平。我们还将比较 TIV 和 LAIV 接受者的流感特异性反应水平。最后，我们将进行基因表达实验，以确定疫苗接种后诱导的基因表达模式，以进一步了解先天性和适应性免疫反应的差异。我们的数据将对母乳喂养期间免疫保护的机制进行全面分析。此外，从该提案中获得的经验和知识将为R01申请奠定基础，以支持进一步研究如何优化这种孕产妇疫苗接种策略，以保护婴儿免受流感和其他传染病的侵害。